Reuters logo
BRIEF-Bone Therapeutics H1 operating loss rises to 6.16 million euros
August 31, 2017 / 5:50 AM / 3 months ago

BRIEF-Bone Therapeutics H1 operating loss rises to 6.16 million euros

Aug 31 (Reuters) - BONE THERAPEUTICS:

* H1 OPERATING LOSS AMOUNTED TO EUR 6.16 MILLION, COMPARED WITH EUR 5.74 MILLION IN H1 2016

* ENDED FIRST SIX MONTHS OF 2017 WITH EUR 12.60 MILLION IN CASH AND CASH EQUIVALENTS

* EXPECTS TO ANNOUNCE INTERIM RESULTS FOR 2 ONGOING PHASE IIA PROGRAMS FOR DELAYED UNION AND SPINAL FUSION WITH ALLOGENEIC PRODUCT ALLOB

* CASH BURN FOR FY 2017 IS EXPECTED TO BE IN RANGE OF EUR 14-15 MILLION

* HAS SUFFICIENT CASH TO CARRY OUT ITS STRATEGIC OBJECTIVES INTO Q2 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below